{
    "eid": "2-s2.0-84949035010",
    "title": "Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study",
    "cover-date": "2016-03-23",
    "subject-areas": [
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        }
    ],
    "keywords": [
        "Bone mineral density",
        "Chronic kidney disease",
        "Emtricitabine",
        "HIV",
        "Tenofovir alafenamide"
    ],
    "authors": [
        "Anton Pozniak"
    ],
    "citedby-count": 169,
    "ref-count": 28,
    "ref-list": [
        "The Kidney in HIV infection: Beyond HIV-associated nephropathy",
        "Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons",
        "Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients",
        "Estimated HIV Incidence in the United States, 2007-2010",
        "Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease",
        "Chronic kidney disease in HIV infection: An urban epidemic",
        "Racial/ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US States, 2005-2008",
        "The new invincibles: HIV screening among older adults in the U.S",
        "Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue",
        "Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects",
        "Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study",
        "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy",
        "The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials",
        "Estimating glomerular filtration rate from serum creatinine and cystatin C",
        "Stribild (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) US Prescribing Information",
        "Emtriva (Emtricitabine) US Prescribing Information",
        "Atripla (Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate) US Prescribing Information",
        "Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in hiv-infected patients",
        "Association of tenofovir exposure with kidney disease risk in HIV infection",
        "Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004-2012",
        "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis",
        "Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts",
        "Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts",
        "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America",
        "Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'",
        "Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
        "American Association of Pharmaceutical Scientists Annual Meeting and Exposition"
    ],
    "affiliation": [
        {
            "affiliation-city": "Denver",
            "affilname": "National Jewish Health",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Berkeley",
            "affilname": "Be Well Medical Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "London",
            "affilname": "Chelsea and Westminster Hospital NHS Foundation Trust",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "London",
            "affilname": "King's College Hospital NHS Foundation Trust",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Madrid",
            "affilname": "Hospital Universitario La Paz",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Indianapolis",
            "affilname": "Indiana University School of Medicine",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Khon Kaen",
            "affilname": "Khon Kaen University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Foster City",
            "affilname": "Gilead Sciences Incorporated",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Houston",
            "affilname": "Crofoot Research Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Fort Pierce",
            "affilname": "Midway Immunology and Research Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "Holdsworth House Medical Practice",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Houston",
            "affilname": "Therapeutic Concepts",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Amgen",
        "Bristol-Myers Squibb",
        "Eli Lilly and Company",
        "Merck",
        "Novartis",
        "Gilead Sciences",
        "Gilead Sciences",
        "Janssen Biotech",
        "AbbVie",
        "Meso Scale Diagnostics",
        "Janssen Pharmaceuticals"
    ]
}